Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh

Pre-Open Stock Movers 07/13: (DPW) (PLXP) (MSEX) Higher; (SLP) (TWO) (AFIB) Lower (more...)

July 13, 2021 9:25 AM EDT

Pre-Open Stock Movers:

Ault Global Holdings, Inc. (NYSE: DPW) 23% HIGHER; Q2 2021 Revenue of Approximately $62 million, up 1048% From the Prior Years Quarter

PLx Pharma Inc. (NASDAQ: PLXP) 16.8% HIGHER; announced that three stock-keeping units (SKUs) of VAZALORE, the first and only U.S. Food and Drug Administration (FDA) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August.

Simulations Plus (NASDAQ: SLP)... More

After-Hours Stock Movers 07/12: (PLXT) (ARDS) (EQ) Higher; (SLP) (TWO) (VOXX) Lower (more...)

July 12, 2021 5:59 PM EDT

After-Hours Stock Movers:

PLx Pharma Inc. (NASDAQ: PLXP) 30.3% HIGHER; announced that three stock-keeping units (SKUs) of VAZALORE, the first and only U.S. Food and Drug Administration (FDA) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August.

Simulations Plus (NASDAQ: SLP) 14.8% LOWER; reported Q3 EPS of $0.18, in-line with the analyst estimate of $0.18. Revenue for the quarter came in at $12.8 million versus the consensus estimate of $14.74 million.

Aridis... More

Celldex (CLDX) Announces up to $175M Share Offering

July 12, 2021 4:01 PM EDT

Celldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $175 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of common stock offered in the public offering. All of the shares of common stock are being offered by the Company. Celldex intends to use the net proceeds from the offering to continue clinical and preclinical development of its product candidates and for... More

Celldex Therapeutics (CLDX) PT Raised to $61 at Cantor Fitzgerald

July 12, 2021 1:22 PM EDT

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $61.00 (from $35.00) while maintaining a Overweight rating.

... More

Celldex Therapeutics (CLDX) Gains on CDX-0159 Update, Which Has Drug 'In the Driver's Seat'

July 12, 2021 10:18 AM EDT

Celldex Therapeutics (NASDAQ: CLDX) shares are ramping 30% in early trading Monday following updated data from the companys ongoing Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.

The update highlights several key metrics:

All 19/19 (100%) patients experienced a clinical response as assessed by provocation threshold testing; 18/19 (95%) experienced a complete response and 1/19 (5%) experienced a partial response.Rapid onset of responses after... More

Pre-Open Stock Movers 07/12: (STFC) (CLDX) (SPI) Higher; (TBLT) (DIDI) (RKT) Lower (more...)

July 12, 2021 9:28 AM EDT

Pre-Open Stock Movers

State Auto Financial Corporation (NASDAQ: STFC) 189% HIGHER; Liberty Mutual Holding Company Inc., State Automobile Mutual Insurance Company, and State Auto Financial Corporation (NASDAQ: STFC) announced today that they have signed a definitive agreement pursuant to which Liberty Mutual would acquire State Auto Group, a super-regional insurance holding company headquartered in Columbus, Ohio. Under the terms of the agreement, State Auto mutual members will become mutual members of Liberty Mutual and Liberty Mutual will acquire all of the publicly held... More

Celldex Therapeutics (CLDX) PT Raised to $50 at H.C. Wainwright

July 12, 2021 6:21 AM EDT

H.C. Wainwright analyst Joseph Pantginis raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $50.00 (from $36.00) while maintaining a Buy rating following updated Phase 1b data from the ongoing Phase 1b study of CDX-0159.

The analyst commented, "Celldex reported updated Phase 1b data from the ongoing Phase 1b study of... More